Initially, we identified that emodin strongly decreased phosphorylated STAT3 in HepG2, SK-HEP-1, and PLC/PRF5 cells (Figure 7A); moreover, the synergistic suppression of STAT3 after the combination of emodin and sorafenib treatment was observed in several HCC cells (Figure 7B). Here, STAT3 is linked to hepatocellular carcinoma.